Clinica BavieraXMAD:CBAV +0.71%100 EBITDA Margin % is 30.31% as of Mar. 2026, which is 8% above its 10-year median of 28.11. GuruFocus rates XMAD:CBAV with a GF Score™ of 100/100 and a GF Value™ of €41.29 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Clinica Baviera ranks better than 87.25% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Clinica Baviera's EBITDA for the
three
months ended in Mar. 2026 was €26.4 Mil. Clinica Baviera's Revenue for the
three
months ended in Mar. 2026 was €87.0 Mil. Therefore, Clinica Baviera's EBITDA margin for the quarter that ended in Mar. 2026 was 30.31%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Clinica Baviera EBITDA Margin % Related Terms
Clinica Baviera EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Clinica Baviera's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:CBAV vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Clinica Baviera's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinica Baviera EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clinica Baviera's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Clinica Baviera's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinica Baviera (XMAD:CBAV) has a EBITDA Margin % of 30.31% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Clinica Baviera and its competitors. This is near median its historical median of 28.11. Over the past decade, Clinica Baviera's EBITDA Margin % has ranged from 18.03 to 30.95. According to the industry distribution chart, Clinica Baviera ranks #26 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 12.7%.
Is Clinica Baviera's EBITDA Margin % too high?
Clinica Baviera's current EBITDA Margin % of 30.31% is near median its 10-year median of 28.11. Over the past 10 years, this metric has ranged from a low of 18.03 to a high of 30.95. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Clinica Baviera's value of 30.31% is 482.9% above this industry median. Based on the distribution chart, Clinica Baviera ranks #26 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Clinica Baviera has a GF Score™ of 100/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clinica Baviera's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clinica Baviera ranks #26 out of 204 companies for EBITDA Margin %. This places Clinica Baviera in the top 13% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. Clinica Baviera's value of 30.31% is 482.9% above this benchmark. Historically, Clinica Baviera's own EBITDA Margin % has ranged from 18.03 to 30.95 over the past decade. While the company's 10-year median is 28.11 vs. the industry median of 5.20, Clinica Baviera has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinica Baviera's current EBITDA Margin % of 30.31% is 482.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Clinica Baviera and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinica Baviera's current EBITDA Margin % is 30.31%, which is near median its own 10-year median of 28.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinica Baviera stock overvalued right now?
Based on GuruFocus' analysis, Clinica Baviera (XMAD:CBAV) is currently considered Significantly Overvalued. The stock's GF Value™ is €41.29, compared to a current price of €56.60 — trading 37.1% above its estimated fair value. The current EBITDA Margin % is 30.31%, which is near median its 10-year median of 28.11 and 482.9% above the Medical Diagnostics & Research industry median of 5.20. Clinica Baviera's overall GF Score™ is 100/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Clinica Baviera (XMAD:CBAV), the current EBITDA Margin % is 30.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinica Baviera (XMAD:CBAV) Overvalued in 2026?
Based on GuruFocus' analysis, Clinica Baviera stock appears to be overvalued.
The current stock price of €56.60 is trading 37.1% above its estimated GF Value™ of €41.29.
GuruFocus considers Clinica Baviera to be Significantly Overvalued.
Key valuation signals for XMAD:CBAV:
EBITDA Margin %: 30.31% (near median its 10-year median of 28.11)
GF Value™: €41.29 vs. price of €56.60 (37.1% above fair value)
Industry Position: 482.9% above the Medical Diagnostics & Research median (#26 of 204)
No single metric tells the full story. See the XMAD:CBAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinica Baviera SA operates ophthalmological clinics. It is involved in the diagnosis, treatment, and monitoring of various types of ophthalmological disorders. It offers diagnosis and treatment for various eye problems such as long-sightedness, short-sightedness, astigmatism, cataracts and eye strain.
100GF Score
Get the complete analysis for XMAD:CBAV
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:CBAV has been successfully added to your 
